Pharmacology of the short QT syndrome N588K-hERG K + channel mutation: Differential impact on selected class I and class III antiarrhythmic drugs

British Journal of Pharmacology

Volumn 155, Issue 6, 2008, Pages 957-966

  McPate, M J ^a   Duncan, R S ^a   Hancox, J C ^a   Witchel, H J ^a,b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

hERG; Human ether go go related gene; I Kr; Inactivation; K V11.1; KCNH2; N588K; QT interval; Rapid delayed rectifier potassium current; Short QT syndrome; SQTS

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; AMIODARONE; ANTIARRHYTHMIC AGENT; DISOPYRAMIDE; POTASSIUM CHANNEL HERG; PROPAFENONE; QUINIDINE; SOTALOL;

ANIMAL CELL; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENCY; MUTATION; NONHUMAN; PATCH CLAMP; PRIORITY JOURNAL; SHORT QT SYNDROME;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; CHO CELLS; CRICETINAE; CRICETULUS; ELECTROPHYSIOLOGY; ETHER-A-GO-GO POTASSIUM CHANNELS; MUTATION; PATCH-CLAMP TECHNIQUES; SYNDROME; TEMPERATURE;

EID: 57349159464     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/bjp.2008.325     Document Type: Article

References (44)

1. Alexander SP, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd edition. Br J Pharmacol 153 (Suppl. 2): S1-S209.
2. Bellocq C, van Ginneken AC, Bezzina CR, Alders M, Escande D, MannensMM et al (2004). Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation 109: 2394-2397.
3. Brugada R, Hong K, Dumaine R, Cordeiro J, Gaita F, Borggrefe M et al (2004). Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 109: 30-35.
4. Chen J, Seebohm G, Sanguinetti MC (2002). Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels. Proc Natl Acad Sci USA 99: 12461-12466.
5. Kr inactivation by mutation N588K in KCNH2: a link to arrhythmogenesis in short QT syndrome. Cardiovasc Res 67: 498-509.
6. Delgado C, Tamargo J, Henzel D, Lorente P (1993). Effects of propafenone on calcium current in guinea-pig ventricular myocytes. Brit J Pharmacol 108: 721-727.
7. Duncan RS, McPate MJ, Ridley JM, Gao Z, James AF, Leishman DJ et al. (2007). Inhibition of the HERG potassium channel by the tricyclic antidepressant doxepin. Biochem Pharmacol 74: 425-437.
8. + channels. Mol Pharmacol 60: 1343-1348.
9. + channels. Circ Res 82: 386-395.
10. Gaita F, Giustetto C, Bianchi F, Schimpf R, Haissaguerre M, Calo L et al. (2004). Short QT syndrome: pharmacological treatment. J Am Coll Cardiol 43: 1494-1499.
11. Gaita F, Giustetto C, Bianchi F,Wolpert C, Schimpf R, Riccardi R et al. (2003). Short QT Syndrome: a familial cause of sudden death. Circulation 108: 965-970.
12. Gussak I, Brugada P, Brugada J, Antzelevitch C, Osbakken M, Bjerregaard P (2002). ECG phenomenon of idiopathic and paradoxical short QT intervals. Card Electrophysiol Rev 6: 49-53.
13. Gussak I, Brugada P, Brugada J, Wright RS, Kopecky SL, Chaitman BR et al. (2000). Idiopathic short QT interval: a new clinical syndrome? Cardiology 94: 99-102.
14. Hancox JC, Mitcheson JS (1997). Inhibition of L-type calcium current by propafenone in single myocytes isolated from the rabbit atrioventricular node. Br J Pharmacol 121: 7-14.
15. Hancox JC,Witchel HJ, Varghese A (1998). Alteration of HERG current profile during the cardiac ventricular action potential, following a pore mutation. Biochem Biophys Res Commun 253: 719-724.
16. Herzberg IM, Trudeau MC, Robertson GA (1998). Transfer of rapid inactivation and sensitivity to the class III antiarrhythmic drug E-4031 from HERG to M-eag channels. J Physiol 511: 3-14.
17. Hong K, Bjerregaard P, Gussak I, Brugada R (2005a). Short QT syndrome and atrial fibrillation caused by mutation in KCNH2. J Cardiovasc Electrophysiol 16: 394-396.
18. Hong K, Piper DR, Diaz-Valdecantos A, Brugada J, Oliva A, Burashnikov E et al. (2005b). De novo KCNQ1 mutation responsible for atrial fibrillation and short QT syndrome in utero. Cardiovasc Res 68: 433-440.
19. Lees-Miller JP, Duan Y, Teng GQ, Duff HJ (2000). Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. Mol Pharmacol 57: 367-374.
20. Levi AJ, Hancox JC, Howarth FC, Croker J, Vinnicombe J (1996). A method for making rapid changes of superfusate whilst maintaining temperature at 37 degrees C. Pflügers Arch 432: 930-937.
21. Lu LX, Zhou W, Zhang X, Cao Q, Yu K, Zhu C (2006). Short QT syndrome: a case report and review of literature. Resuscitation 71: 115-121.
22. + channel mutation in the 'short QT syndrome': mechanism of gain-in-function determined at 37 1C. Biochem Biophys Res Commun 334: 441-449.
23. + channels involved in variant 1 short QT syndrome. J Mol Cell Cardiol 41: 563-566.
24. Milnes JT, Crociani O, Arcangeli A, Hancox JC, Witchel HJ (2003). Blockade of HERG potassiumcurrents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. Br J Pharmacol 139: 887-898.
25. Mitcheson JS, Chen J, Lin M, Culberson C, Sanguinetti MC (2000). A structural basis for drug-induced long QT syndrome. Proc Natl Acad Sci USA 97: 12329-12333.
26. Numaguchi H, Mullins FM, Johnson Jr JP, Johns DC, Po SS, Yang IC et al. (2000). Probing the interaction between inactivation gating and D-sotalol block of HERG. Circ Res 87: 1012-1018.
27. Paul A, Witchel HJ, Hancox JC (2001). Inhibition of HERG potassium channel current by the class 1a antiarrhythmic agent disopyramide. Biochem Biophys Res Commun 280: 1243-1250.
28. Paul AA, Witchel HJ, Hancox JC (2002). Inhibition of the current of heterologously expressed HERG potassium channels by flecainide and comparison with quinidine, propafenone and lignocaine. Br J Pharmacol 136: 717-729.
29. Priori SG, Pandit SV, Rivolta I, Berenfeld O, Ronchetti E, Dhamoon A et al. (2005). A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res 96: 800-807.
30. Redfern WS, Carlsson L, Davis AS, Lynch WG, MacKenzie I, Palethorpe S et al. (2003). Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 58: 32-45.
31. + channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656. Biochem Biophys Res Commun 325: 883-891.
32. Robertson GA (2000). LQT2: amplitude reduction and loss of selectivity in the tail that wags the HERG channel. Circ Res 86: 492-493.
33. + channel inhibition by disopyramide in patients with a short QT-1 syndrome: a pilot study. J Cardiovasc Electrophysiol 18: 1157-1160.
34. Schimpf R, Wolpert C, Bianchi F, Giustetto C, Gaita F, Bauersfeld U et al. (2003). Congenital short QT syndrome and implantable cardioverter defibrillator treatment: inherent risk for inappropriate shock delivery. J Cardiovasc Electrophysiol 14: 1273-1277.
35. Schimpf R, Wolpert C, Gaita F, Giustetto C, Borggrefe M (2005). Short QT syndrome. Cardiovasc Res 67: 357-366.
36. Smith PL, Baukrowitz T, Yellen G (1996). The inward rectification mechanism of the HERG cardiac potassium channel. Nature 379: 833-836.
37. Teschemacher AG, Seward EP, Hancox JC, Witchel HJ (1999). Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline. Br J Pharmacol 128: 479-485.
38. Witchel HJ (2007). The hERG potassium channel as a therapeutic target. Expert Opin Ther Targets 11: 321-336.
39. Witchel HJ, Dempsey CE, Sessions RB, Perry M, Milnes JT, Hancox JC et al. (2004). The low potency, voltage-dependent HERG blocker propafenone - molecular determinants and drug trapping. Mol Pharmacol 66: 1201-1212.
40. Wolpert C, Schimpf R, Giustetto C, Antzelevitch C, Cordeiro J, Dumaine R et al. (2005). Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol 16: 54-58.
41. Yang BF, Xu DH, Xu CQ, Li Z, Du ZM, Wang HZ et al. (2004). Inactivation gating determines drug potency: a common mechanism for drug blockade of HERG channels. Acta Pharmacol Sin 25: 554-560.
42. Zhang S, Zhou Z, Gong Q, Makielski JC, January CT (1999). Mechanism of block and identification of the verapamil binding domain to HERG potassium channels. Circ Res 84: 989-998.
43. Zhou Z, Gong Q, Ye B, Makielski JC, Robertson GA, January CT (1998). Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature. Biophys J 74: 230-241.
44. + channels expressed in Xenopus oocytes reduces rectification by shifting the voltage dependence of inactivation. J Physiol (London) 509: 129-137.